Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile.

Vázquez S, Lázaro M, Fírvida JL, Santomé L, Afonso J, Amenedo M, Casal J; Galician Lung Cancer Group (GGCP).

Anticancer Drugs. 2014 Apr;25(4):368-74. doi: 10.1097/CAD.0000000000000066.

PMID:
24384805
[PubMed - in process]
3.

Second- and third-line treatments in non-small cell lung cancer.

Kumar A, Wakelee H.

Curr Treat Options Oncol. 2006 Jan;7(1):37-49. Review.

PMID:
16343367
[PubMed - indexed for MEDLINE]
4.
5.

Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.

Zugazagoitia J, Puente J, González-Larriba JL, Manzano A, Sotelo M, Hernández S, Sanz J, Pérez P, Díaz-Rubio E.

Oncology. 2013;84(5):255-64. doi: 10.1159/000346534. Epub 2013 Feb 20.

PMID:
23428780
[PubMed - indexed for MEDLINE]
6.

Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?

Gebbia V.

Expert Opin Pharmacother. 2008 Jun;9(8):1321-37. doi: 10.1517/14656566.9.8.1321 . Review.

PMID:
18473707
[PubMed - indexed for MEDLINE]
7.

Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.

Lyseng-Williamson KA.

Pharmacoeconomics. 2010;28(1):75-92. doi: 10.2165/10482880-000000000-00000.

PMID:
20014878
[PubMed - indexed for MEDLINE]
8.

Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.

Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, Nguyen B, Paul S, McAndrews P, Bunn PA Jr, Kelly K.

J Clin Oncol. 2006 Sep 20;24(27):4405-11. Erratum in: J Clin Oncol. 2006 Dec 1;24(34):5477.

PMID:
16983108
[PubMed - indexed for MEDLINE]
Free Article
9.

Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients.

Li R, Sun L, Wang J, Qian J, Wang Z, Jiao X.

Pulm Pharmacol Ther. 2012 Oct;25(5):364-70. doi: 10.1016/j.pupt.2012.06.008. Epub 2012 Jul 3.

PMID:
22766314
[PubMed - indexed for MEDLINE]
10.

Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study.

Minami S, Kijima T, Takahashi R, Kida H, Nakatani T, Hamaguchi M, Takeuchi Y, Nagatomo I, Yamamoto S, Tachibana I, Komuta K, Kawase I.

BMC Cancer. 2012 Jul 18;12:296. doi: 10.1186/1471-2407-12-296.

PMID:
22809298
[PubMed - indexed for MEDLINE]
Free PMC Article
11.
12.

Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.

Silvestri GA, Rivera MP.

Chest. 2005 Dec;128(6):3975-84. Review.

PMID:
16354869
[PubMed - indexed for MEDLINE]
13.

A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.

Jäkel A, Plested M, Dharamshi K, Modha R, Bridge S, Johns A.

Appl Health Econ Health Policy. 2013 Feb;11(1):27-43. doi: 10.1007/s40258-012-0001-1. Review.

PMID:
23329379
[PubMed - indexed for MEDLINE]
14.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.

Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.

Health Technol Assess. 2001;5(32):1-195. Review.

PMID:
12065068
[PubMed - indexed for MEDLINE]
Free Article
15.

Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.

Vergnenegre A, Corre R, Berard H, Paillotin D, Dujon C, Robinet G, Crequit J, Bota S, Thomas P, Chouaid C; 0506 GFPC Team.

J Thorac Oncol. 2011 Jan;6(1):161-8. doi: 10.1097/JTO.0b013e318200f4c1.

PMID:
21150465
[PubMed - indexed for MEDLINE]
16.

Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy.

Schwander B, Ravera S, Giuliani G, Nuijten M, Walzer S.

Clinicoecon Outcomes Res. 2012;4:237-43. doi: 10.2147/CEOR.S34371. Epub 2012 Sep 3.

PMID:
22969300
[PubMed]
Free PMC Article
17.

Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.

Farina G, Longo F, Martelli O, Pavese I, Mancuso A, Moscetti L, Labianca R, Bertolini A, Cortesi E, Farris A, Fagnani D, Locatelli MC, Valmadre G, Ardizzoia A, Tomirotti M, Rulli E, Garassino MC, Scanni A.

Clin Lung Cancer. 2011 Mar;12(2):138-41. doi: 10.1016/j.cllc.2011.03.008. Epub 2011 Apr 11.

PMID:
21550561
[PubMed - indexed for MEDLINE]
18.

[Advance of second-line chemotherapy in advanced non-small cell lung cancer.].

Zhang L.

Zhongguo Fei Ai Za Zhi. 2008 Feb 20;11(1):4-9. doi: 10.3779/j.issn.1009-3419.2008.01.002. Chinese.

PMID:
20727256
[PubMed]
Free Article
19.

Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.

Ng R, Loreto M, Lee R, Leighl NB.

Lung Cancer. 2008 Aug;61(2):262-5. doi: 10.1016/j.lungcan.2008.02.002. Epub 2008 Mar 20.

PMID:
18358559
[PubMed - indexed for MEDLINE]
20.

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Adis International Ltd.

Drugs R D. 2003;4(4):243-8.

PMID:
12848590
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk